Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press7310.17650/2222-1468-2012-0-2-92-96REVIEWОБЗОРНАЯ СТАТЬЯCURRENT APPROACHES TO TREATING NON-RHABDOID SOFT TISSUE SARCOMAS OF THE HEAD AND NECK IN CHILDREN: A REVIEW OF LITERATUREСОВРЕМЕННЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ НЕРАБДОИДНЫХ САРКОМ МЯГКИХ ТКАНЕЙ ГОЛОВЫ И ШЕИ У ДЕТЕЙ (ОБЗОР ЛИТЕРАТУРЫ)BolotinM. V.БолотинМ. В.
Russian Federation
bolotin1980@mail.ruLopatinA. V.ЛопатинА. В.
Russian Federation
Russian Children’s Clinical Hospital, Ministry of Health of Russia, MoscowФГБУ «Российская детская клиническая больница» Минздрава России, Москва150420122292961804201518042015Copyright ©; 2012, Bolotin M.V., Lopatin A.V.Copyright ©; 2012, Болотин М.В., Лопатин А.В.2012Bolotin M.V., Lopatin A.V.Болотин М.В., Лопатин А.В.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/73

Soft tissue sarcomas constitute approximately 8–10 % of all malignancies in children and adolescents and half of them are rhabdomyosarcoma. The second half makes up a heterogeneous group of malignancies of mesenchymal non-rhabdoid origin, which have been recently referred to as an individual group of non-rhabdoid soft tissue sarcomas (an adult type) in increasing frequency. The choice of a treatment option depends on a number of factors: its histological structure, location, stage of a tumor; the possible performance of radical surgery; and the grade of tumor differentiation. Surgery is the basic treatment; if it is impossible, chemoradiotherapy is performed at stage 1. 

Саркомы мягких тканей составляют около 8–10 % всех злокачественных опухолей у детей и подростков и половина из них представлена рабдомиосаркомой. Вторая половина представлена гетерогенной группой злокачественных опухолей мезенхимального нерабдоидного происхождения, которые в последнее время все чаще выделяются в отдельную группу нерабдоидных сарком мягких тканей («взрослый тип»). Выбор метода лечения зависит от ряда факторов — гистологического строения, локализации образования; стадии; возможности выполнения радикального оперативного вмешательства; степени дифференцировки опухоли. Основной метод лечения — оперативное вмешательство, при его невозможности на первом этапе проводится химиолучевое лечение.

non-rhabdoid soft tissue sarcomaschildrenhead and neck tumorsprinciples of treatment and diagnosisнерабдоидные саркомы мягких тканейдетиопухоли головы и шеипринципы лечения и диагностики1. Ferrari A., Casanova M. Specification on the definition of adult-type soft tissue sarcoma. J Clin Oncol 2006;24(24):4042−3.Ferrari A., Casanova M. Specification on the definition of adult-type soft tissue sarcoma. J Clin Oncol 2006;24(24):4042−3.2. Grovas A., Fremgen A., Rauck A. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 1997;80:2321−32.Grovas A., Fremgen A., Rauck A. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer 1997;80:2321−32.3. Gurney J.G., Smith M.A., Ross J.A. SEER Cancer incidence and survival among children and adolescents: United States SEER Program 1975−1995. National Institutes of Health: 99-4649.Gurney J.G., Smith M.A., Ross J.A. SEER Cancer incidence and survival among children and adolescents: United States SEER Program 1975−1995. National Institutes of Health: 99-4649.4. Cancer Epidemiology in Older Adolescents and Young Adults 1975−2000. National Institutes of Health: 06-5767.Cancer Epidemiology in Older Adolescents and Young Adults 1975−2000. National Institutes of Health: 06-5767.5. Rao B.N. Nonrhabdomyosarcoma in children: prognostic factors influencing survival. Semin Surg Oncol 1993;9(6):524−31.Rao B.N. Nonrhabdomyosarcoma in children: prognostic factors influencing survival. Semin Surg Oncol 1993;9(6):524−31.6. Spunt S.L., Poquette C.A., Hurt Y.S. et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children’s Research Hospital. J Clin Oncol 1999; 17(12):3697−705.Spunt S.L., Poquette C.A., Hurt Y.S. et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children’s Research Hospital. J Clin Oncol 1999; 17(12):3697−705.7. Andrassy R.J. Advances in the surgical management of sarcomas in children. Am J Surg 2002;184(6):484−91.Andrassy R.J. Advances in the surgical management of sarcomas in children. Am J Surg 2002;184(6):484−91.8. Hayes-Jordan A.A., Spunt S.L., Poquette C.A. et al. Nonrhabdomyosarcoma soft tissue sarcomas in children: is age at diagnosis an important variable? J Pediatr Surg 2000; 35(6):948−54.Hayes-Jordan A.A., Spunt S.L., Poquette C.A. et al. Nonrhabdomyosarcoma soft tissue sarcomas in children: is age at diagnosis an important variable? J Pediatr Surg 2000; 35(6):948−54.9. Ferrari A., Casanova M., Collini P. et al. Adult-type soft tissue sarcomas in pediatricage patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol 2005 June 20; 23(18):4021−30.Ferrari A., Casanova M., Collini P. et al. Adult-type soft tissue sarcomas in pediatricage patients: experience at the Istituto Nazionale Tumori in Milan. J Clin Oncol 2005 June 20; 23(18):4021−30.10. Rao B.N., Etcubanas E.E., Green A.A. Present-day concepts in the management of sarcomas in children. Cancer Invest 1989; 7(4):349−56.Rao B.N., Etcubanas E.E., Green A.A. Present-day concepts in the management of sarcomas in children. Cancer Invest 1989; 7(4):349−56.11. Dillon P.W., Maurer H., Jenkins J. et al. A prospective study of nonrhabdomyosarcoma soft tissue sarcomas in the pediatric age group. J Pediatr Surg 1992;27:241−5.Dillon P.W., Maurer H., Jenkins J. et al. A prospective study of nonrhabdomyosarcoma soft tissue sarcomas in the pediatric age group. J Pediatr Surg 1992;27:241−5.12. Pappo A.S., Rao B.N., Jenkins J. et al. Metastatic nonrhabdomyosarcomatous soft-tissue sarcomas in children and adolescents: the St. Jude Children’s Research Hospital experience. Med Pediatr Oncol 1999; 33(2):76−82.Pappo A.S., Rao B.N., Jenkins J. et al. Metastatic nonrhabdomyosarcomatous soft-tissue sarcomas in children and adolescents: the St. Jude Children’s Research Hospital experience. Med Pediatr Oncol 1999; 33(2):76−82.13. Rao B.N. Nonrhabdomyosarcoma in children: prognostic factors influencing survival. Semin Surg Oncol 1993; 9(6):524−31.Rao B.N. Nonrhabdomyosarcoma in children: prognostic factors influencing survival. Semin Surg Oncol 1993; 9(6):524−31.14. Andrassy R.J. Advances in the surgical management of sarcomas in children. Am J Surg 2002;184(6):484−91.Andrassy R.J. Advances in the surgical management of sarcomas in children. Am J Surg 2002;184(6):484−91.15. Paulino A.C., Ritchie J., Wen B.C. The value of postoperative radiotherapy in childhood nonrhabdomyosarcoma soft tissue sarcoma. Pediatr Blood Cancer 2004; 43:587−93.Paulino A.C., Ritchie J., Wen B.C. The value of postoperative radiotherapy in childhood nonrhabdomyosarcoma soft tissue sarcoma. Pediatr Blood Cancer 2004; 43:587−93.16. Mark R.J., Poen J., Tran L.M. et al. Postirradiation sarcomas. A single-institution study and review of the literature. Cancer 1994; 73(10):2653−62.Mark R.J., Poen J., Tran L.M. et al. Postirradiation sarcomas. A single-institution study and review of the literature. Cancer 1994; 73(10):2653−62.17. Kuttesch J.F. Jr, Wexler L.H., Marcus R.B. et al. Second malignancies after Ewing’s sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996; 14(10):2818−25.Kuttesch J.F. Jr, Wexler L.H., Marcus R.B. et al. Second malignancies after Ewing’s sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996; 14(10):2818−25.18. Hawkins M.M. Second primary tumors following radiotherapy for childhood cancer. Int J Radiat Oncol Biol Phys 1990 Nov; 19(5):1297−301.Hawkins M.M. Second primary tumors following radiotherapy for childhood cancer. Int J Radiat Oncol Biol Phys 1990 Nov; 19(5):1297−301.19. Meadows A.T. Second malignant neoplasms in childhood cancer survivors. J Assoc Pediatr Oncol Nurses 1989; 6(1):7−11.Meadows A.T. Second malignant neoplasms in childhood cancer survivors. J Assoc Pediatr Oncol Nurses 1989; 6(1):7−11.20. Pratt C.B., Pappo A.S., Gieser P. et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. J Clin Oncol 1999;17(4):1219−26.Pratt C.B., Pappo A.S., Gieser P. et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: A Pediatric Oncology Group Study. J Clin Oncol 1999;17(4):1219−26.21. Yang J.C., Chang A.E., Baker A.R. et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197−203.Yang J.C., Chang A.E., Baker A.R. et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197−203.22. Ferrari A. Role of chemotherapy in pediatric nonrhabdomyosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther 2008; 8(6);929−38.Ferrari A. Role of chemotherapy in pediatric nonrhabdomyosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther 2008; 8(6);929−38.23. Pappo A.S., Devidas M., Jenkins J. et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advancedstage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 2005;23(18): 4031−7.Pappo A.S., Devidas M., Jenkins J. et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advancedstage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol 2005;23(18): 4031−7.24. Nathan P.C., Tsokos M., Long L. et al. Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience. Pediatr Blood Cancer 2005; 44(5):449−54.Nathan P.C., Tsokos M., Long L. et al. Adjuvant chemotherapy for the treatment of advanced pediatric nonrhabdomyosarcoma soft tissue sarcoma: the National Cancer Institute experience. Pediatr Blood Cancer 2005; 44(5):449−54.25. Daw N.C., Billups C.A., Pappo A.S. et al. Malignant fibrous histiocytoma and other fibrohistiocytic tumors in pediatric patients: the St. Jude Children’s Research Hospital experience. Cancer 2003;97(11): 2839−47.Daw N.C., Billups C.A., Pappo A.S. et al. Malignant fibrous histiocytoma and other fibrohistiocytic tumors in pediatric patients: the St. Jude Children’s Research Hospital experience. Cancer 2003;97(11): 2839−47.26. Wan X., Helman L.J. The biology behind mTOR inhibition in sarcoma. Oncologist 2007;12:1007−18.Wan X., Helman L.J. The biology behind mTOR inhibition in sarcoma. Oncologist 2007;12:1007−18.27. Heymach J.V. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol 2001;12:261−9.Heymach J.V. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol 2001;12:261−9.